Neurizon’s NUZ-001 Breaks Blood-Brain Barrier, Reverses ALS Protein Aggregation

• NUZ-001 and NUZ-001 Sulfone cross the blood-brain barrier in rodent studies
• Achieved brain concentrations align with those reversing TDP-43 aggregation in ALS models
• Significant prevention of TDP-43 aggregation confirmed across tested doses
• Findings support NUZ-001’s potential as a disease-modifying therapy for ALS and related disorders